Squamous Cell Lung Carcinoma
📧 Sign up to get email alerts when something new happens for Squamous Cell Lung Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
A completed clinical trial update for Lung-MAP exploring biomarker-targeted second-line therapy in recurrent stage IV squamous cell lung can…
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating durvalumab and tremelimumab in recurrent stage IV squamous cell lung carcinoma has completed with results …
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers [Phase 3]
Phase 3 trial evaluating nivolumab with or without ipilimumab as second-line therapy for recurrent stage IV squamous cell lung cancer withou…
-
CLINICAL_TRIALS trial_result · 2021-12-30Clinical Trial Update: Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers [Phase 2, Phase 3]
Clinical trial update for Durvalumab as second-line therapy in recurrent stage IV squamous cell lung cancer without matching biomarkers; tri…
-
CLINICAL_TRIALS trial_result · 2021-06-29Clinical Trial Update: Lung-MAP S1400K: c-MET Positive [Phase 2]
Phase 2 clinical trial update for c-MET positive recurrent/stage IV squamous cell lung carcinoma (Lung-MAP S1400K) completed with results po…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating talazoparib in HRR gene mutation-positive recurrent stage IV squamous cell lung cancer has completed with results p…
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer [Phase 2, Phase 3]
Clinical trial update for AZD4547 as second-line therapy in FGFR-positive recurrent stage IV squamous cell lung cancer (Phase 2/Phase 3) com…
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer [Phase 2, Phase 3]
Clinical trial update for Palbociclib as second-line therapy in CCND gene amplification–positive recurrent stage IV squamous cell lung cance…
-
CLINICAL_TRIALS trial_result · 2020-03-25Clinical Trial Update: An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) [Phase 2]
Phase II open-label trial comparing nivolumab plus ipilimumab versus platinum-based chemotherapy plus nivolumab in chemonaive metastatic or …
-
CLINICAL_TRIALS trial_result · 2020-03-19Clinical Trial Update: Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches [Phase 2, Phase 3]
A Phase 2/3 trial evaluating rilotumumab with erlotinib versus erlotinib alone in MET-positive, recurrent stage IV squamous cell lung cancer…
-
CLINICAL_TRIALS trial_result · 2019-12-17Clinical Trial Update: TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) [Phase 2]
Phase 2 trial update for TAS-102 in previously treated unresectable or metastatic squamous cell lung carcinoma has completed with results po…
-
CLINICAL_TRIALS trial_result · 2019-03-06Clinical Trial Update: Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches [Phase 2]
Phase 2 trial update for taselisib as therapy in patients with stage IV squamous cell lung cancer and matching biomarkers; trial completed w…